The expression and significance of p4E‐BP1/4E‐BP1 in prostate cancer-Reference-Cited by-同舟云学术

The expression and significance of p4E‐BP1/4E‐BP1 in prostate cancer

Published:2022-03-08 Issue:4 Volume:36 Page:
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:Clinical Laboratory Analysis

Author:

Wang Kai‐yun¹,Wang Ke‐jie²³,Ma Qi²³⁴^ORCID

Affiliation:

1. School of Medicine Ningbo University Ningbo Zhejiang China

2. Translational Research Laboratory for Urology the Key Laboratory of Ningbo City Ningbo First Hospital The Affiliated Hospital of Ningbo University Ningbo Zhejiang China

3. Ningbo Clinical Research Center for Urological Disease Ningbo Zhejiang China

4. Comprehensive Urogenital Cancer Center Ningbo First Hospital The Affiliated Hospital of Ningbo University Ningbo Zhejiang China

Funder

Natural Science Foundation of Zhejiang Province

Natural Science Foundation of Ningbo

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcla.24332

Reference16 articles.

1. Cancer statistics, 2020

2. Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin’s lymphoma: evidence from a meta-analysis

3. Global cancer statistics, 2012

4. Urinary biomarkers of prostate cancer

5. 4E-BP1 as an oncotarget

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Protective Effects of an Aged Black Garlic Water Extract on the Prostate;Nutrients;2024-09-07

2. A critical role of protein damage response in mediating cancer drug resistance;2024-07-19

3. LncRNA LINC01133 Targeting miR-141-5p to Mediate the Progression and Ameliorate Poor Prognosis of Prostate Cancer;Russian Journal of Genetics;2023-12

4. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer;Biomedicine & Pharmacotherapy;2023-12